GARP promotes the proliferation and therapeutic resistance of bone sarcoma cancer cells through the activation of TGF-β.

Cell Death & Disease
Ana Belén Carrillo-GálvezPer Anderson

Abstract

Sarcomas are mesenchymal cancers with poor prognosis, representing about 20% of all solid malignancies in children, adolescents, and young adults. Radio- and chemoresistance are common features of sarcomas warranting the search for novel prognostic and predictive markers. GARP/LRRC32 is a TGF-β-activating protein that promotes immune escape and dissemination in various cancers. However, if GARP affects the tumorigenicity and treatment resistance of sarcomas is not known. We show that GARP is expressed by human osteo-, chondro-, and undifferentiated pleomorphic sarcomas and is associated with a significantly worse clinical prognosis. Silencing of GARP in bone sarcoma cell lines blocked their proliferation and induced apoptosis. In contrast, overexpression of GARP promoted their growth in vitro and in vivo and increased their resistance to DNA damage and cell death induced by etoposide, doxorubicin, and irradiation. Our data suggest that GARP could serve as a marker with therapeutic, prognostic, and predictive value in sarcoma. We propose that targeting GARP in bone sarcomas could reduce tumour burden while simultaneously improving the efficacy of chemo- and radiotherapy.

References

Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefan S BielackKurt Winkler
Apr 20, 2005·Journal of Pediatric Hematology/oncology·Cynthia E Herzog
Apr 5, 2007·Nature Protocols·Nicolaas A P FrankenChris van Bree
Sep 27, 2008·Journal of Leukocyte Biology·Andrew W Taylor
Dec 31, 2008·Cell Research·Ying E Zhang
Aug 5, 2009·Proceedings of the National Academy of Sciences of the United States of America·Dat Q TranEthan M Shevach
Aug 12, 2009·Proceedings of the National Academy of Sciences of the United States of America·Rui WangDerya Unutmaz
Aug 13, 2010·Nature·Simón Méndez-FerrerPaul S Frenette
Oct 22, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J S WhelanH Gelderblom
Jul 20, 2012·International Journal of Biological Sciences·Erin C ConnollyRosemary J Akhurst
Oct 20, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C A StillerUNKNOWN RARECARE Working Group
May 8, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Qihui ZhouAlla Skapenko
Jan 29, 2014·Cancer Chemotherapy and Pharmacology·Atif A AhmedLars Wagner
Oct 17, 2014·Molecular Cancer Research : MCR·Jae Youn YiMary Helen Barcellos-Hoff
Jun 2, 2016·Oncotarget·Susanne A HahnAndrea Tuettenberg
Jul 2, 2016·Stem Cells International·Ander AbarrategiRene Rodriguez
Aug 9, 2016·Frontiers in Oncology·Lucia Centurione, Francesca B Aiello
Jun 14, 2017·The Journal of Immunology : Official Journal of the American Association of Immunologists·Olivier DedobbeleerSophie Lucas
Aug 11, 2017·Molecular BioSystems·Julie StockisSophie Lucas
Dec 1, 2017·Neoplasia : an International Journal for Oncology Research·Juan TorninRene Rodriguez
Feb 25, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Silvia C FormentiWilliam H McBride
Jun 30, 2018·Cytokine & Growth Factor Reviews·Virgínea de Araújo FariasPer Anderson
Nov 18, 2018·Endocrine Pathology·Xiaoxu ZhangFu Ren
Apr 18, 2019·Immunity·Eduard Batlle, Joan Massagué
Feb 20, 2020·Stem Cells Translational Medicine·Ana Belén Carrillo-GálvezPer Anderson
Oct 1, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P G CasaliUNKNOWN ESMO Guidelines Committee, PaedCan and ERN EURACAN. Electronic address: clinicalguidelines@esmo.org
Mar 27, 2020·Frontiers in Cardiovascular Medicine·Warisara ParichatikanondHitoshi Kurose

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
ELISA

Software Mentioned

xCELLigence
GraphPad Prism
SPSS

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis